Golden State Wealth Management LLC Has $35,000 Stock Holdings in Sanofi (NASDAQ:SNY)

Golden State Wealth Management LLC boosted its holdings in Sanofi (NASDAQ:SNY) by 619.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 633 shares of the company’s stock after acquiring an additional 545 shares during the quarter. Golden State Wealth Management LLC’s holdings in Sanofi were worth $35,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Lee Danner & Bass Inc. bought a new position in Sanofi in the 4th quarter valued at about $31,000. Bessemer Group Inc. lifted its position in shares of Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after buying an additional 242 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company’s stock worth $62,000 after buying an additional 264 shares in the last quarter. AdvisorNet Financial Inc lifted its position in shares of Sanofi by 16.4% during the 1st quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company’s stock worth $89,000 after buying an additional 227 shares in the last quarter. Finally, ORG Wealth Partners LLC bought a new position in shares of Sanofi during the 1st quarter worth approximately $91,000. Institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

SNY has been the topic of several recent analyst reports. Barclays reissued an “overweight” rating on shares of Sanofi in a research report on Wednesday. Guggenheim reissued a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. BNP Paribas started coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 target price on the stock. Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target on the stock. Three analysts have rated the stock with a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $61.50.

Sanofi Trading Up 0.5%

NASDAQ:SNY opened at $49.31 on Thursday. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $120.93 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 1.01 and a beta of 0.48. The firm’s 50 day moving average is $50.77 and its 200 day moving average is $52.03. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.04. The company had revenue of $10.41 billion for the quarter, compared to analysts’ expectations of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. Sanofi’s revenue was down 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.78 EPS. Sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were paid a $2.0369 dividend. This represents a yield of 3.1%. This is a positive change from Sanofi’s previous annual dividend of $1.48. The ex-dividend date of this dividend was Friday, May 9th. Sanofi’s payout ratio is currently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.